• Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
31
Jul
2017

Whither Experts? A Review of The Death of Expertise and Some Thoughts for Biopharma

/
Kyle Serikawa
/
0
/
All, People, Politics
31 Jul 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
24
Jul
2017

How Agios, Neurocrine Are Striving to Go Commercial, and Hold Onto Their Souls

/
Luke Timmerman
/
1
/
All, People
24 Jul 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
21
Jul
2017

Vertex’s Grand Slam for CF, Puma Stretches on Price, Sarepta & BioMarin Bury the Hatchet

/
Luke Timmerman
/
0
/
All
21 Jul 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Jul
2017

Family Offices: Quietly Putting Money to Work in Biotech Startups

/
Luke Timmerman
/
0
/
All
19 Jul 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
14
Jul
2017

Novartis’ Big CAR-T Moment, Amicus Exits FDA Penalty Box, and Evelo’s Bold $50M Microbiome Play

/
Luke Timmerman
/
0
/
All
14 Jul 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
11
Jul
2017

A One-Bug Drug For the Immune System? Evelo Gets $50M to Test Concept

/
Luke Timmerman
/
1
/
All, Cancer, Venture Capital
11 Jul 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
10
Jul
2017

Allergan’s Social Contract, One Year Later: CEO Brent Saunders Reflects on the Expected and Unexpected

/
Luke Timmerman
/
1
/
All, The Edge
10 Jul 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
7
Jul
2017

Konica’s Precision Medicine Power Play, Endo Yanks Opioid, Celgene’s PD-1 Foray

/
Luke Timmerman
/
1
/
All
07 Jul 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
5
Jul
2017

So You Think Your Drug Could Be Best-in-Class? What If the World Changes?

/
Nagesh Mahanthappa
/
1
/
All, Strategy
05 Jul 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
30
Jun
2017

Merck’s CV Surprise, FDA Clamors for Generics and Amgen & Illumina’s Precision Medicine Win

/
Luke Timmerman
/
0
/
All
30 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
29
Jun
2017

How to Find Biotech Startup Cash, With or Without Traditional VCs

/
Luke Timmerman
/
0
/
All, Venture Capital
29 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
26
Jun
2017

Watershed Moments: When Celgene and Bristol-Myers Squibb Became Deal Winners

/
Luke Timmerman
/
0
/
All, People, The Edge
26 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
23
Jun
2017

Senate Healthcare Overhaul Advances, Novartis Nails CV Study, Clovis Cashes In on PARP Win

/
Luke Timmerman
/
0
/
All
23 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
22
Jun
2017

Repare Secures $68M Series A to Discover ‘Synthetic Lethal’ Cancer Drugs

/
Luke Timmerman
/
2
/
All, Cancer, Venture Capital
22 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
21
Jun
2017

Rubius Snags $120M to Engineer Red Blood Cell Therapies Off The Shelf

/
Luke Timmerman
/
0
/
All, Venture Capital
21 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
20
Jun
2017

Plants in Space Might Be Trying to Tell Us Something Cautionary About Precision Medicine

/
Kyle Serikawa
/
0
/
All, Genomics
20 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Jun
2017

An American Sickness: A Skillful Deconvolution of the U.S. Healthcare Mess

/
Luke Timmerman
/
2
/
All, The Edge
19 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
16
Jun
2017

Supreme Court Speeds Biosimilars, Clancy’s Lucrative Switch, & Apple Sniffs Around Health Records

/
Luke Timmerman
/
0
/
All
16 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
15
Jun
2017

Do’s and Don’ts for Startup Boards

/
Robert More
/
4
/
All, Venture Capital
15 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
12
Jun
2017

Long-Distance Relationships in Biotech Startups: How to Make Them Work

/
Luke Timmerman
/
0
/
All, The Edge
12 Jun 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 61 62 63 64 65 … 79 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial
testimonial
testimonial

View More Testimonials ➛

Twitter

Tweets by ldtimmerman Follow @ldtimmerman
© Copyright 2025, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder